2398. Utilization Practices of Ceftazidime–Avibactam at Academic Medical Centers in the United States

BACKGROUND: Ceftazidime–avibactam (CAV) was US FDA-approved for complicated intra-abdominal/urinary tract infections in 2015, and for hospital-acquired/ventilator-associated pneumonia in 2018. However, little is known about its real-world use. METHODS: Encounters of inpatients receiving CAV at acade...

Descripción completa

Detalles Bibliográficos
Autores principales: Strich, Jeffrey R, Ricotta, Emily, Lai, Yi Ling, Hohmann, Samuel, Hussain, Sadia, Rhee, Chanu, Klompas, Michael, Palmore, Tara N, III, John H Powers, Dekker, John P, Adjemian, Jennifer, Danner, Robert L, Kadri, Sameer S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253798/
http://dx.doi.org/10.1093/ofid/ofy210.2051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253798/
http://dx.doi.org/10.1093/ofid/ofy210.2051

Ejemplares similares